<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TINDAMAX- tinidazole tablet, film coated </strong><br>Mission Pharmacal Company<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">Tindamax<span class="Sup">®</span> (tinidazole) oral tablets<br>These highlights do not include all the information needed to use Tindamax<span class="Sup">®</span> safely and effectively. See full prescribing information for Tindamax. Tindamax<span class="Sup">®</span> (tinidazole) oral tablets for oral solution. Initial U.S. Approval 2004</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: POTENTIAL RISK FOR CARCINOGENICITY</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<p class="Highlighta"><span class="Bold">Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent (<a href="#S13-1">13.1</a>). Although such data have not been reported for tinidazole, the two drugs are structurally related and have similar biologic effects.  Use should be limited to approved indications only.</span> </p>
</div></div>
<div><div><p class="Highlighta">To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tindamax and other antibacterial drugs, Tindamax should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.   (<a href="#section-11.3">11.3</a>)</p></div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"><span class="XmChange">Indications and Usage, <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial Vaginosis</span> (<a href="#S1-4">1.4</a>)        5/2007</span> </p>
<p class="Highlighta"><span class="XmChange">Dosage and Administration, <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial Vaginosis</span> (<a href="#S2-6">2.6</a>)                            5/2007</span> </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: POTENTIAL RISK FOR CARCINOGENICITY</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<p class="Highlighta"><span class="Bold">Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent (<a href="#S13-1">13.1</a>). Although such data have not been reported for tinidazole, the two drugs are structurally related and have similar biologic effects.  Use should be limited to approved indications only.</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Tindamax is a nitroimidazole antimicrobial indicated for: </p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">Trichomoniasis</span> (<a href="#S1-1">1.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">Giardiasis</span>: in patients age 3 and older (<a href="#S1-2">1.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span>: in patients age 3 and older (<a href="#S1-3">1.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial Vaginosis</span>: in non-pregnant, adult women (<a href="#S1-4">1.4, </a><a href="#S8-1">8.1</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">Trichomoniasis</span>:  a single 2 g oral dose taken with food. Treat sexual partners with the same dose and at the same time (<a href="#S2-3">2.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">Giardiasis</span>:  Adults: a single 2 g dose taken with food. Pediatric patients older than three years of age: a single dose of 50 mg/kg (up to 2 g) with food (<a href="#S2-4">2.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span>, <span class="Italics">Intestinal:</span> Adults: 2 g per day for 3 days with food. Pediatric patients older than three years of age: 50 mg/kg/day (up to 2 g per day) for 3 days with food (<a href="#S2-5">2.5</a>). <span class="Italics">Amebic <span class="product-label-link" type="condition" conceptid="201901" conceptname="Abscess of liver">liver abscess</span>:</span> Adults: 2 g per day for 3-5 days with food. Pediatric patients older than three years of age: 50 mg/kg/day (up to 2 g per day) for 3-5 days with food (<a href="#S2-5">2.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial vaginosis</span>: Non-pregnant, adult women:  2 g once daily for 2 days taken with food, or 1 g once daily for 5 days taken with food (<a href="#S2-6">2.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 250 mg and 500 mg (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Prior history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to tinidazole or other nitroimidazole derivatives (<a href="#S4">4, </a><a href="#S6-1">6.1, </a><a href="#S6-2">6.2</a>)</li>
<li>First trimester of pregnancy (<a href="#S4">4, </a><a href="#S8-1">8.1</a>)</li>
<li>Nursing mothers, unless breast-feeding is interrupted during tinidazole therapy and for 3 days following the last dose (<a href="#S4">4, </a><a href="#S8-3">8.3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> have been reported.  Discontinue Tindamax if abnormal neurologic signs develop (<a href="#S5-1">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">Vaginal candidiasis</span> may develop with Tindamax and require treatment with an antifungal agent (<a href="#S5-2">5.2</a>)</li>
<li>Use Tindamax with caution in patients with <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>.  Tindamax may produce transient <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (<a href="#S5-3">5.3, </a><a href="#S7-3">7.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions for a single 2 g dose of tinidazole (incidence &gt;1%) are metallic/bitter taste, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>/<span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>/<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>/<span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (<a href="#S6-1">6.1</a>) </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Mission Pharmacal Company at 1-855-778-0177or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">The following drug interactions were reported for metronidazole, a chemically-related nitroimidazole and may therefore occur with tinidazole: </p>
<ul class="Disc">
<li>Warfarin and other oral coumarin anticoagulants: Anticoagulant dosage may need adjustment during and up to 8 days after tinidazole therapy (<a href="#S7-1">7.1</a>)</li>
<li>Alcohol-containing beverages/preparations: Avoid during and up to 3 days after tinidazole therapy (<a href="#S7-1">7.1</a>)</li>
<li>Lithium: Monitor serum lithium concentrations (<a href="#S7-1">7.1</a>)</li>
<li>Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs (<a href="#S7-1">7.1</a>)</li>
<li>Fluorouracil: Monitor for fluorouracil-associated toxicities (<a href="#S7-1">7.1</a>)</li>
<li>Phenytoin, fosphenytoin: Adjustment of anticonvulsant and/or tinidazole dose(s) may be needed (<a href="#S7-1">7.1, </a><a href="#S7-2">7.2</a>)</li>
<li>CYP3A4 inducers/inhibitors: Monitor for decreased tinidazole effect or increased adverse reactions (<a href="#S7-2">7.2</a>)</li>
</ul>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<ul class="Disc">
<li>Pediatric Use: Data on tinidazole use in children is limited to treatment of <span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">giardiasis</span> and <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> in patients age 3 and older (<a href="#S8-4">8.4</a>)</li>
<li>Hemodialysis patients: If tinidazole is administered the same day and prior to hemodialysis, administer an additional ½ dose after end of hemodialysis (<a href="#S8-6">8.6, </a><a href="#S12-3">12.3</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold">See <a href="#S17">17</a> for PATIENT COUNSELING INFORMATION</span> </p>
<p class="Highlighta"><span class="Bold">Revised: 5/2007</span> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsRevision">Revised: 1/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: POTENTIAL RISK FOR CARCINOGENICITY</span></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1  INDICATIONS AND USAGE</span></a></h1>
<h2><a href="#section-1.1" class="toc">1.1  <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">Trichomoniasis</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2  <span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">Giardiasis</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3  <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span></a></h2>
<h2><a href="#section-1.4" class="toc">1.4  <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial Vaginosis</span></a></h2>
<h1><a href="#section-2" class="toc"><span class="Bold">2  DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc">2.1  Dosing Instructions</a></h2>
<h2><a href="#section-2.2" class="toc">2.2  Compounding of the Oral Suspension</a></h2>
<h2><a href="#section-2.3" class="toc">2.3  <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">Trichomoniasis</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4  <span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">Giardiasis</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5  <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span></a></h2>
<h2><a href="#section-2.6" class="toc">2.6  <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial Vaginosis</span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3  DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4  CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5  WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc">5.1  Neurological Adverse Reactions</a></h2>
<h2><a href="#section-5.2" class="toc">5.2  <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">Vaginal Candidiasis</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3  <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasia</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4  <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6  ADVERSE REACTIONS</span></a></h1>
<h2><a href="#section-6.1" class="toc">6.1  Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2  Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7  DRUG INTERACTIONS</span></a></h1>
<h2><a href="#section-7.1" class="toc">7.1  Potential Effects of Tinidazole on Other Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2  Potential Effects of Other Drugs on Tinidazole</a></h2>
<h2><a href="#section-7.3" class="toc">7.3  Laboratory Test Interactions</a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8  USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3  Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5  Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10  OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11  DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12  CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3  Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4  Microbiology</a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13  NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2  Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14  CLINICAL STUDIES</span></a></h1>
<h2><a href="#section-13.1" class="toc">14.1  <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">Trichomoniasis</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2  <span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">Giardiasis</span></a></h2>
<h2><a href="#section-13.3" class="toc">14.3  Intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span></a></h2>
<h2><a href="#section-13.4" class="toc">14.4  Amebic <span class="product-label-link" type="condition" conceptid="201901" conceptname="Abscess of liver">Liver Abscess</span></a></h2>
<h2><a href="#section-13.5" class="toc">14.5  <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial Vaginosis</span></a></h2>
<h1><a href="#section-14" class="toc"><span class="Bold">16  HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h2><a href="#section-14.1" class="toc"></a></h2>
<h2><a href="#section-15.1" class="toc">17.1  Administration of Drug</a></h2>
<h2><a href="#section-15.2" class="toc">17.2  Alcohol Avoidance</a></h2>
<h2><a href="#section-15.3" class="toc">17.3  <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="Gd2e669"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: POTENTIAL RISK FOR CARCINOGENICITY</span></h1>
<p class="First"><a name="p211221357159758"></a>Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent (<a href="#S13-1">13.1</a>). Although such data have not been reported for tinidazole, the two drugs are structurally related and have similar biologic effects.  <span class="Bold">Its use should be reserved for the conditions described in INDICATIONS AND USAGE (<a href="#S1">1</a>).</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">1  INDICATIONS AND USAGE</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1-1"></a><a name="section-1.1"></a><p></p>
<h2>1.1  <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">Trichomoniasis</span></h2>
<p class="First"><a name="p5441221357159758"></a>Tinidazole is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">trichomoniasis</span> caused by <span class="Italics">Trichomonas vaginalis.</span> The organism should be identified by appropriate diagnostic procedures. Because <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">trichomoniasis</span> is a <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted disease</span> with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span><span class="Italics">[see Clinical Studies (<a href="#S14-1">14.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1-2"></a><a name="section-1.2"></a><p></p>
<h2>1.2  <span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">Giardiasis</span></h2>
<p class="First"><a name="p7691221357159758"></a>Tinidazole is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">giardiasis</span> caused by <span class="Italics">Giardia duodenalis</span> (also termed <span class="Italics">G. lamblia</span>) in both adults and pediatric patients older than three years of age <span class="Italics">[see Clinical Studies (<a href="#S14-2">14.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1-3"></a><a name="section-1.3"></a><p></p>
<h2>1.3  <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span></h2>
<p class="First"><a name="p7921221357159758"></a>Tinidazole is indicated for the treatment of intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> and amebic <span class="product-label-link" type="condition" conceptid="201901" conceptname="Abscess of liver">liver abscess</span> caused by <span class="Italics">Entamoeba histolytica</span> in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> passage <span class="Italics">[see Clinical Studies (<a href="#S14-3">14.3, </a><a href="#S14-4">14.4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1-4"></a><a name="section-1.4"></a><p></p>
<h2>1.4  <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial Vaginosis</span></h2>
<p class="First"><a name="p8141221357159758"></a>Tinidazole is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> (formerly referred to as <span class="Italics">Haemophilus</span> <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="Italics">Gardnerella</span> <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, nonspecific <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, or anaerobic vaginosis) in non-pregnant women <span class="Italics">[see Use in Specific Populations (<a href="#S8-1">8.1</a>) and Clinical Studies (<a href="#S14-5">14.5</a>)].</span></p>
<p><a name="p10421221357159758"></a>Other pathogens commonly associated with <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">vulvovaginitis</span> such as <span class="Italics">Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span> and <span class="Italics">Herpes simplex</span> virus should be ruled out.</p>
<p><a name="p10531221357159758"></a>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tindamax and other antibacterial drugs, Tindamax should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">2  DOSAGE AND ADMINISTRATION</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2-1"></a><a name="section-2.1"></a><p></p>
<h2>2.1  Dosing Instructions</h2>
<p class="First"><a name="p13181221357159758"></a>It is advisable to take tinidazole with food to minimize the incidence of <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span> and other gastrointestinal side-effects.  Food does not affect the oral bioavailability of tinidazole <span class="Italics">[see Clinical Pharmacology (<a href="#S12-3">12.3</a>)].</span></p>
<p><a name="p13281221357159758"></a>Alcoholic beverages should be avoided when taking tinidazole and for 3 days afterwards <span class="Italics">[see Drug Interactions (<a href="#S7-1">7.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2-2"></a><a name="section-2.2"></a><p></p>
<h2>2.2  Compounding of the Oral Suspension</h2>
<p class="First"><a name="p15491221357159758"></a>For those unable to swallow tablets, tinidazole tablets may be crushed in artificial cherry syrup to be taken with food.</p>
<p><a name="p15521221357159758"></a><span class="Italics">Procedure for Extemporaneous Pharmacy Compounding of the Oral Suspension:</span> Pulverize four 500 mg oral tablets with a mortar and pestle. Add approximately 10 mL of cherry syrup to the powder and mix until smooth. Transfer the suspension to a graduated amber container. Use several small rinses of cherry syrup to transfer any remaining drug in the mortar to the final suspension for a final volume of 30 mL. The suspension of crushed tablets in artificial cherry syrup is stable for 7 days at room temperature. When this suspension is used, it should be shaken well before each administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2-3"></a><a name="section-2.3"></a><p></p>
<h2>2.3  <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">Trichomoniasis</span></h2>
<p class="First"><a name="p15631221357159758"></a>The recommended dose in both females and males is a single 2 g oral dose taken with food. Since <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">trichomoniasis</span> is a <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted disease</span>, sexual partners should be treated with the same dose and at the same time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2-4"></a><a name="section-2.4"></a><p></p>
<h2>2.4  <span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">Giardiasis</span></h2>
<p class="First"><a name="p15711221357159758"></a>The recommended dose in adults is a single 2 g dose taken with food. In pediatric patients older than three years of age, the recommended dose is a single dose of 50 mg/kg (up to 2 g) with food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2-5"></a><a name="section-2.5"></a><p></p>
<h2>2.5  <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Gd2e1089"></a><a name="section-2.5.1"></a><p></p>
<h3></h3>
<p class="First"><a name="p15831221357159758"></a><span class="Italics">Intestinal:</span> The recommended dose in adults is a 2 g dose per day for 3 days taken with food. In pediatric patients older than three years of age, the recommended dose is 50 mg/kg/day (up to 2 g per day) for 3 days with food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gd2e1110"></a><a name="section-2.5.2"></a><p></p>
<h3></h3>
<p class="First"><a name="p17991221357159758"></a><span class="Italics">Amebic <span class="product-label-link" type="condition" conceptid="201901" conceptname="Abscess of liver">Liver Abscess</span>:</span> The recommended dose in adults is a 2 g dose per day for 3-5 days taken with food. In pediatric patients older than three years of age, the recommended dose is 50 mg/kg/day (up to 2 g per day) for 3-5 days with food. There are limited pediatric data on durations of therapy exceeding 3 days, although a small number of children were treated for 5 days without additional reported adverse reactions.  Children should be closely monitored when treatment durations exceed 3 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2-6"></a><a name="section-2.6"></a><p></p>
<h2>2.6  <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial Vaginosis</span></h2>
<p class="First"><a name="p18101221357159758"></a>The recommended dose in non-pregnant females is a 2 g oral dose once daily for 2 days taken with food or a 1 g oral dose once daily for 5 days taken with food.  The use of tinidazole in pregnant patients has not been studied for <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">3  DOSAGE FORMS AND STRENGTHS</span></h1>
<ul class="Disc">
<li>250 mg tablets are pink, round, scored tablets, with TM debossed on one side and 250 on the other</li>
<li>500 mg tablets are pink, oval, scored tablets, with TM debossed on one side and 500 on the other</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">4  CONTRAINDICATIONS</span></h1>
<p class="First"><a name="p20501221357159758"></a>The use of tinidazole is contraindicated:</p>
<ul class="Disc">
<li>In patients with a previous history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to tinidazole or other nitroimidazole derivatives.  Reported reactions have ranged in severity from <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> to <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> <span class="Italics">[see Adverse Reactions (<a href="#S6-1">6.1, </a><a href="#S6-2">6.2</a>)].</span>
</li>
<li>During first trimester of pregnancy <span class="Italics">[see Use in Specific Populations (<a href="#S8-1">8.1</a>)].</span>
</li>
<li>In nursing mothers: Interruption of breast-feeding is recommended during tinidazole therapy and for 3 days following the last dose <span class="Italics">[see Use in Specific Populations (<a href="#S8-3">8.3</a>)].</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">5  WARNINGS AND PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5-1"></a><a name="section-5.1"></a><p></p>
<h2>5.1  Neurological Adverse Reactions</h2>
<p class="First"><a name="p25771221357159758"></a><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsive seizures</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, the latter characterized mainly by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of an extremity, have been reported in patients treated with tinidazole. The appearance of abnormal neurologic signs demands the prompt discontinuation of tinidazole therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5-2"></a><a name="section-5.2"></a><p></p>
<h2>5.2  <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">Vaginal Candidiasis</span></h2>
<p class="First"><a name="p25851221357159758"></a>The use of tinidazole may result in <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>.  In a clinical study of 235 women who received tinidazole for <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>, a vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> developed in 11 (4.7%) of  all study subjects <span class="Italics">[see Clinical Studies (<a href="#S14-5">14.5</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5-3"></a><a name="section-5.3"></a><p></p>
<h2>5.3  <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasia</span></h2>
<p class="First"><a name="p26041221357159758"></a>Tinidazole should be used with caution in patients with evidence of or history of <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span> <span class="Italics">[see Drug Interactions (<a href="#S7-3">7.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5-4"></a><a name="section-5.4"></a><p></p>
<h2>5.4  <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></h2>
<p class="First"><a name="p28251221357159758"></a>Prescribing Tindamax in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">6  ADVERSE REACTIONS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6-1"></a><a name="section-6.1"></a><p></p>
<h2>6.1  Clinical Studies Experience</h2>
<p class="First"><a name="p28491221357159758"></a>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><a name="p28521221357159758"></a>Among 3669 patients treated with a single 2 g dose of tinidazole, in both controlled and uncontrolled <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">trichomoniasis</span> and <span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">giardiasis</span> clinical studies, adverse reactions were reported by 11.0% of patients. For multi-day dosing in controlled and uncontrolled <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> studies, adverse reactions were reported by 13.8% of 1765 patients. Common (≥ 1% incidence) adverse reactions reported by body system are as follows. (Note: Data described in Table 1 below are pooled from studies with variable designs and safety evaluations.)</p>
<p><a name="p28551221357159758"></a><span class="Italics">Other adverse reactions reported with tinidazole include:</span></p>
<p><a name="p28601221357159758"></a>Central Nervous System: Two serious adverse reactions reported include <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and transient <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> including <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> <span class="Italics">[see Warnings and Precautions (<a href="#S5-1">5.1</a>)].</span> Other CNS reports include <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">giddiness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>.</p>
<p><a name="p30771221357159758"></a>Gastrointestinal: <span class="product-label-link" type="condition" conceptid="4217621" conceptname="Black hairy tongue">tongue discoloration</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></p>
<p><a name="p30801221357159758"></a><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, pruritis, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, dryness of mouth, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span></p>
<p><a name="p30831221357159758"></a>Renal: darkened urine</p>
<p><a name="p30861221357159758"></a>Cardiovascular: <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span></p>
<p><a name="p30891221357159758"></a>Hematopoietic: transient <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, transient <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span></p>
<p><a name="p30921221357159758"></a>Other: <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> overgrowth, increased <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral candidiasis</span>, hepatic abnormalities including raised transaminase level, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, and <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>.</p>
<a name="t30991221357159760"></a><table width="55%">
<caption><span>Table 1. Adverse Reactions Summary of Published Reports          </span></caption>
<col align="left" valign="middle" width="60%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule" align="left"> </td>
<td class="Lrule" align="center">2 g single dose</td>
<td class="Lrule Rrule" align="center">Multi-day dose</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"> GI:      Metallic/bitter taste</td>
<td class="Lrule" align="center">3.7%</td>
<td class="Lrule Rrule" align="center">6.3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">           <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule" align="center">3.2%</td>
<td class="Lrule Rrule" align="center">4.5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">           <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Lrule" align="center">1.5%</td>
<td class="Lrule Rrule" align="center">2.5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">           <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>/<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>/<span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span></td>
<td class="Lrule" align="center" valign="middle">1.8%</td>
<td class="Lrule Rrule" align="center" valign="middle">1.4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">           <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule" align="center">1.5%</td>
<td class="Lrule Rrule" align="center">0.9%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">           <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Lrule" align="center">0.4%</td>
<td class="Lrule Rrule" align="center">1.4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"> CNS:  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>/<span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></td>
<td class="Lrule" align="center">2.1%</td>
<td class="Lrule Rrule" align="center">1.1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">           <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule" align="center">1.1%</td>
<td class="Lrule Rrule" align="center">0.5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"> Other: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule" align="center">1.3%</td>
<td class="Lrule Rrule" align="center">0.7%</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"> Total patients with adverse reactions</td>
<td class="Lrule" align="center">11.0%<br>(403/3669)</td>
<td class="Lrule Rrule" align="center">13.8%<br>(244/1765)</td>
</tr>
</tbody>
</table>
<p><a name="p38511221357159758"></a>Rare reported adverse reactions include <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, furry tongue, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> and reversible <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><a name="p38541221357159758"></a><span class="Italics">Adverse Reactions in Pediatric Patients:</span> In pooled pediatric studies, adverse reactions reported in pediatric patients taking tinidazole were similar in nature and frequency to adult findings including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, taste change, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
<p><a name="p38601221357159758"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial vaginosis</span>: </span> The most common adverse reactions in treated patients (incidence &gt;2%), which were not identified in the <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">trichomoniasis</span>, <span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">giardiasis</span> and <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> studies, are gastrointestinal: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>; renal: <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">painful urination</span>, and <span class="product-label-link" type="condition" conceptid="4298419" conceptname="Cloudy urine">urine abnormality</span>; and other reactions including <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span>, vulvo-<span class="product-label-link" type="condition" conceptid="4012205" conceptname="Vaginal discomfort">vaginal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4162573" conceptname="Vaginal odor">vaginal odor</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> <span class="Italics">[See Clinical Studies (<a href="#S14-5">14.5</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6-2"></a><a name="section-6.2"></a><p></p>
<h2>6.2  Postmarketing Experience</h2>
<p class="First"><a name="p38781221357159758"></a>The following adverse reactions have been identified and reported during post-approval use of Tindamax.  Because the reports of these reactions are voluntary and the population is of uncertain size, it is not always possible to reliably estimate the frequency of the reaction or establish a causal relationship to drug exposure.</p>
<p><a name="p38811221357159758"></a>   Severe acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported on initial or subsequent exposure to tinidazole.  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> may include <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, pruritis, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">7  DRUG INTERACTIONS</span></h1>
<p class="First"><a name="p40971221357159758"></a>Although not specifically identified in studies with tinidazole, the following drug interactions were reported for metronidazole, a chemically-related nitroimidazole.  Therefore, these drug interactions may occur with tinidazole.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7-1"></a><a name="section-7.1"></a><p></p>
<h2>7.1  Potential Effects of Tinidazole on Other Drugs</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Gd2e1699"></a><a name="section-7.1.1"></a><p></p>
<h3></h3>
<p class="First"><a name="p43741221357159759"></a><span class="Italics">Warfarin and Other Oral Coumarin Anticoagulants:</span> As with metronidazole, tinidazole may enhance the effect of warfarin and other coumarin anticoagulants, resulting in a prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.  The dosage of oral anticoagulants may need to be adjusted during tinidazole co-administration and up to 8 days after discontinuation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gd2e1720"></a><a name="section-7.1.2"></a><p></p>
<h3></h3>
<p class="First"><a name="p43841221357159759"></a><span class="Italics">Alcohols, Disulfiram:</span> Alcoholic beverages and preparations containing ethanol or propylene glycol should be avoided during tinidazole therapy and for 3 days afterward because <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> may occur.  <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reactions</span> have been reported in alcoholic patients using metronidazole and disulfiram concurrently.  Though no similar reactions have been reported with tinidazole, tinidazole should not be given to patients who have taken disulfiram within the last two weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gd2e1740"></a><a name="section-7.1.3"></a><p></p>
<h3></h3>
<p class="First"><a name="p43941221357159759"></a><span class="Italics">Lithium:</span> Metronidazole has been reported to elevate serum lithium levels.  It is not known if tinidazole shares this property with metronidazole, but consideration should be given to measuring serum lithium and creatinine levels after several days of simultaneous lithium and tinidazole treatment to detect potential lithium <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gd2e1760"></a><a name="section-7.1.4"></a><p></p>
<h3></h3>
<p class="First"><a name="p46101221357159759"></a><span class="Italics">Phenytoin, Fosphenytoin:</span> Concomitant administration of oral metronidazole and intravenous phenytoin was reported to result in prolongation of the half-life and reduction in the clearance of phenytoin.  Metronidazole did not significantly affect the pharmacokinetics of orally-administered phenytoin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gd2e1780"></a><a name="section-7.1.5"></a><p></p>
<h3></h3>
<p class="First"><a name="p46201221357159759"></a><span class="Italics">Cyclosporine, Tacrolimus:</span> There are several case reports suggesting that metronidazole has the potential to increase the levels of cyclosporine and tacrolimus.  During tinidazole co-administration with either of these drugs, the patient should be monitored for signs of calcineurin-inhibitor associated toxicities.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Gd2e1800"></a><a name="section-7.1.6"></a><p></p>
<h3></h3>
<p class="First"><a name="p46301221357159759"></a><span class="Italics">Fluorouracil:</span> Metronidazole was shown to decrease the clearance of fluorouracil, resulting in an increase in side-effects without an increase in therapeutic benefits. If the concomitant use of tinidazole and fluorouracil cannot be avoided, the patient should be monitored for fluorouracil-associated toxicities.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7-2"></a><a name="section-7.2"></a><p></p>
<h2>7.2  Potential Effects of Other Drugs on Tinidazole</h2>
<p class="First"><a name="p46411221357159759"></a><span class="Italics">CYP3A4 Inducers and Inhibitors:</span> Simultaneous administration of tinidazole with drugs that induce liver microsomal enzymes, i.e., CYP3A4 inducers such as <span class="Italics">phenobarbital, rifampin, phenytoin,</span> and <span class="Italics">fosphenytoin</span> (a pro-drug of phenytoin), may accelerate the elimination of tinidazole, decreasing the plasma level of tinidazole.  Simultaneous administration of drugs that inhibit the activity of liver microsomal enzymes, i.e., CYP3A4 inhibitors such as <span class="Italics">cimetidine</span> and <span class="Italics">ketoconazole,</span> may prolong the half-life and decrease the plasma clearance of tinidazole, increasing the plasma concentrations of tinidazole.</p>
<p><a name="p48691221357159759"></a><span class="Italics">Cholestyramine:</span> Cholestyramine was shown to decrease the oral bioavailability of metronidazole by 21%. Thus, it is advisable to separate dosing of cholestyramine and tinidazole to minimize any potential effect on the oral bioavailability of tinidazole.</p>
<p><a name="p48751221357159759"></a><span class="Italics">Oxytetracycline:</span> Oxytetracycline was reported to antagonize the therapeutic effect of metronidazole.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="S7-3"></a><a name="section-7.3"></a><p></p>
<h2>7.3  Laboratory Test Interactions</h2>
<p class="First"><a name="p48861221357159759"></a>Tinidazole, like metronidazole, may interfere with certain types of determinations of serum chemistry values, such as <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and hexokinase glucose. Values of zero may be observed.  All of the assays in which interference has been reported involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide adenine dinucleotide (NAD <span class="Sup">+</span>↔ NADH).  Potential interference is due to the similarity of absorbance peaks of NADH and tinidazole.</p>
<p><a name="p48931221357159759"></a>Tinidazole, like metronidazole, may produce transient <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>; however, no persistent hematological abnormalities attributable to tinidazole have been observed in clinical studies. Total and differential leukocyte counts are recommended if re-treatment is necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">8  USE IN SPECIFIC POPULATIONS</span></h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8-1"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First"><a name="p51491221357159759"></a><span class="Bold">Teratogenic effects: Pregnancy Category C</span></p>
<p><a name="p51541221357159759"></a>The use of tinidazole in pregnant patients has not been studied.   Since tinidazole crosses the placental barrier and enters fetal circulation it should not be administered to pregnant patients in the first trimester.</p>
<p><a name="p51571221357159759"></a>Embryo-fetal developmental toxicity studies in pregnant mice indicated no embryo-fetal toxicity or malformations at the highest dose level of 2,500 mg/kg (approximately 6.3-fold the highest human therapeutic dose based upon body surface area conversions). In a study with pregnant rats a slightly higher incidence of fetal mortality was observed at a maternal dose of 500 mg/kg (2.5-fold the highest human therapeutic dose based upon body surface area conversions).  No biologically relevant neonatal developmental effects were observed in rat neonates following maternal doses as high as 600 mg/kg (3-fold the highest human therapeutic dose based upon body surface area conversions). Although there is some evidence of mutagenic potential and animal reproduction studies are not always predictive of human response, the use of tinidazole after the first trimester of pregnancy requires that the potential benefits of the drug be weighed against the possible risks to both the mother and the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8-3"></a><a name="section-8.2"></a><p></p>
<h2>8.3  Nursing Mothers</h2>
<p class="First"><a name="p51651221357159759"></a>Tinidazole is excreted in breast milk in concentrations similar to those seen in serum.  Tinidazole can be detected in breast milk for up to 72 hours following administration.  Interruption of breast-feeding is recommended during tinidazole therapy and for 3 days following the last dose.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8-4"></a><a name="section-8.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First"><a name="p53791221357159759"></a>Other than for use in the treatment of <span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">giardiasis</span> and <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> in pediatric patients older than three years of age, safety and effectiveness of tinidazole in pediatric patients have not been established.</p>
<p><a name="p53821221357159759"></a><span class="Italics">Pediatric Administration:</span> For those unable to swallow tablets, tinidazole tablets may be crushed in artificial cherry syrup, to be taken with food <span class="Italics">[see Dosage and Administration (<a href="#S2-2">2.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8-5"></a><a name="section-8.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First"><a name="p54001221357159759"></a>Clinical studies of tinidazole did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8-6"></a><a name="section-8.5"></a><p></p>
<h2>8.6  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><a name="p54081221357159759"></a>Because the pharmacokinetics of tinidazole in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCL &lt; 22 mL/min) are not significantly different from those in healthy subjects, no dose adjustments are necessary in these patients.</p>
<p><a name="p54111221357159759"></a><span class="Italics">Patients undergoing hemodialysis:</span> If tinidazole is administered on the same day as and prior to hemodialysis, it is recommended that an additional dose of tinidazole equivalent to one-half of the recommended dose be administered after the end of the hemodialysis <span class="Italics">[see Clinical Pharmacology (<a href="#S12-3">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8-7"></a><a name="section-8.6"></a><p></p>
<h2>8.7  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"><a name="p56351221357159759"></a>There are no data on tinidazole pharmacokinetics in patients with impaired hepatic function.  Reduced elimination of metronidazole, a chemically-related nitroimidazole, has been reported in this population.  Usual recommended doses of tinidazole should be administered cautiously in patients with hepatic dysfunction <span class="Italics">[see Clinical Pharmacology (<a href="#S12-3">12.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">10  OVERDOSAGE</span></h1>
<p class="First"><a name="p56521221357159759"></a>There are no reported <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> with tinidazole in humans.</p>
<p><a name="p56551221357159759"></a><span class="Italics">Treatment of Overdosage:</span> There is no specific antidote for the treatment of overdosage with tinidazole; therefore, treatment should be symptomatic and supportive.  Gastric lavage may be helpful. Hemodialysis can be considered because approximately 43% of the amount present in the body is eliminated during a 6-hour hemodialysis session.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">11  DESCRIPTION</span></h1>
<p class="First"><a name="p56681221357159759"></a>Tinidazole is a synthetic antiprotozoal and antibacterial agent.  It is 1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitroimidazole, a second-generation  2-methyl-5-nitroimidazole, which has the following chemical structure:</p>
<div class="Figure"><img alt="struct-tinidazole" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0d01539-8413-4703-94cc-d221918630a1&amp;name=tindamax-image01.jpg"></div>
<p><a name="p56731221357159759"></a>Tindamax pink oral tablets contain 250 mg or 500 mg of tinidazole.  Inactive ingredients include croscarmellose sodium, FD&amp;C Red 40 lake, FD&amp;C Yellow 6 lake, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, pregelatinized corn starch, titanium dioxide, and triacetin.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">12  CLINICAL PHARMACOLOGY</span></h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12-1"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First"><a name="p58941221357159759"></a>Tinidazole is an antiprotozoal, antibacterial agent. <span class="Italics">[See Clinical Pharmacology (<a href="#S12-4">12.4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12-3"></a><a name="section-11.2"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First"><a name="p59091221357159759"></a><span class="Italics">Absorption:</span> After oral administration, tinidazole is rapidly and completely absorbed.  A bioavailability study of Tindamax tablets was conducted in adult healthy volunteers.  All subjects received a single oral dose of 2 g (four 500 mg tablets) of Tindamax following an overnight fast.  Oral administration of four 500 mg tablets of Tindamax under fasted conditions produced a mean peak plasma concentration (C<span class="Sub">max</span>) of 47.7 (±7.5) µg/mL with a mean time to peak concentration (T<span class="Sub">max</span>) of 1.6 (±0.7) hours, and a mean area under the plasma concentration-time curve (AUC, 0-∞) of 901.6 (± 126.5) µg/hr/mL at 72 hours.  The elimination half-life (T<span class="Sub">1/2</span>) was 13.2 (±1.4) hours.  Mean plasma levels decreased to 14.3 µg/mL at 24 hours, 3.8 µg/mL at 48 hours and 0.8 µg/mL at 72 hours following administration.  Steady-state conditions are reached in 2½ - 3 days of multi-day dosing.</p>
<p><a name="p59271221357159759"></a>Administration of Tindamax tablets with food resulted in a delay in T<span class="Sub">max</span> of approximately 2 hours and a decline in C<span class="Sub">max</span> of approximately 10%<span class="Sub">,</span> compared to fasted conditions.  However, administration of Tindamax with food did not affect AUC or T<span class="Sub">1/2</span> in this study.</p>
<p><a name="p61521221357159759"></a>In healthy volunteers, administration of crushed Tindamax tablets in artificial cherry syrup, [prepared as described in <span class="Italics"> Dosage and Administration (<a href="#S2-2">2.2</a>)</span>] after an overnight fast had no effect on any pharmacokinetic parameter as compared to tablets swallowed whole under fasted conditions.</p>
<p><a name="p61631221357159759"></a><span class="Italics">Distribution:</span> Tinidazole is distributed into virtually all tissues and body fluids and also crosses the blood-brain barrier.  The apparent volume of distribution is about 50 liters.  Plasma protein binding of tinidazole is 12%.  Tinidazole crosses the placental barrier and is secreted in breast milk.</p>
<p><a name="p61691221357159759"></a><span class="Italics">Metabolism:</span> Tinidazole is significantly metabolized in humans prior to excretion.  Tinidazole is partly metabolized by oxidation, hydroxylation, and conjugation.  Tinidazole is the major drug-related constituent in plasma after human treatment, along with a small amount of the 2-hydroxymethyl metabolite.</p>
<p><a name="p61751221357159759"></a>Tinidazole is biotransformed mainly by CYP3A4.  In an <span class="Italics">in vitro</span> metabolic drug interaction study, tinidazole concentrations of up to 75 µg/mL did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4.</p>
<p><a name="p61821221357159759"></a>The potential of tinidazole to induce the metabolism of other drugs has not been evaluated.</p>
<p><a name="p61851221357159759"></a><span class="Italics">Elimination:</span> The plasma half-life of tinidazole is approximately 12-14 hours.  Tinidazole is excreted by the liver and the kidneys.  Tinidazole is excreted in the urine mainly as unchanged drug (approximately 20-25% of the administered dose).  Approximately 12% of the drug is excreted in the feces.</p>
<p><a name="p61911221357159759"></a><span class="Italics">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>:</span> The pharmacokinetics of tinidazole in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCL &lt; 22 mL/min) are not significantly different from the pharmacokinetics seen in healthy subjects.  However, during hemodialysis, clearance of tinidazole is significantly increased; the half-life is reduced from 12.0 hours to 4.9 hours.  Approximately 43% of the amount present in the body is eliminated during a 6-hour hemodialysis session <span class="Italics">[see Use in Specific Populations (<a href="#S8-6">8.6</a>)].</span> The pharmacokinetics of tinidazole in patients undergoing routine continuous peritoneal dialysis have not been investigated.</p>
<p><a name="p64111221357159759"></a><span class="Italics">Patients with impaired hepatic function:</span> There are no data on tinidazole pharmacokinetics in patients with impaired hepatic function.  Reduction of metabolic elimination of metronidazole, a chemically-related nitroimidazole, in patients with hepatic dysfunction has been reported in several studies <span class="Italics">[see Use in Specific Populations (<a href="#S8-7">8.7</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="S12-4"></a><a name="section-11.3"></a><p></p>
<h2>12.4  Microbiology</h2>
<p class="First"><a name="p64291221357159759"></a><span class="Italics">Mechanism of Action:</span> Tinidazole is an antiprotozoal, antibacterial agent. The nitro- group of tinidazole is reduced by cell extracts of <span class="Italics">Trichomonas.</span>  The free nitro- radical generated as a result of this reduction may be responsible for the antiprotozoal activity.  Chemically reduced tinidazole was shown to release nitrites and cause damage to purified bacterial DNA <span class="Italics">in vitro.</span>  Additionally, the drug caused DNA base changes in bacterial cells and DNA strand breakage in mammalian cells. The mechanism by which tinidazole exhibits activity against <span class="Italics">Giardia</span> and <span class="Italics">Entamoeba</span> species is not known.</p>
<p><a name="p66571221357159759"></a><span class="Italics">Antibacterial:</span> Culture and sensitivity testing of bacteria are not routinely performed to establish the diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> <span class="Italics">[see Indications and Usage (<a href="#S1-4">1.4</a>)];</span> standard methodology for the susceptibility testing of potential bacterial pathogens, <span class="Italics">Gardnerella vaginalis, Mobiluncus spp.</span> or <span class="Italics">Mycoplasma hominis,</span> has not been defined. The following <span class="Italics">in vitro</span> data are available, but their clinical significance is unknown.  Tinidazole is active <span class="Italics">in vitro</span> against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms that have been reported to be associated with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>:</p>
<dl class="None">
<dt> </dt>
<dd><span class="Italics">Bacteroides spp.</span></dd>
<dt> </dt>
<dd><span class="Italics">Gardnerella vaginalis</span></dd>
<dt> </dt>
<dd><span class="Italics">Prevotella spp.</span></dd>
</dl>
<p><a name="p69191221357159759"></a>Tinidazole does not appear to have activity against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of vaginal lactobacilli.</p>
<p><a name="p69221221357159759"></a><span class="Italics">Antiprotozoal:</span> Tinidazole demonstrates activity both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> against the following protozoa:<span class="Italics">Trichomonas vaginalis; Giardia duodenalis</span> (also termed <span class="Italics">G. lamblia</span>); and <span class="Italics">Entamoeba histolytica.</span></p>
<p><a name="p69431221357159759"></a>For protozoal parasites, standardized susceptibility tests do not exist for use in clinical microbiology laboratories.</p>
<p><a name="p69461221357159759"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span>:</span> The development of resistance to tinidazole by <span class="Italics">G. duodenalis, E. histolytica,</span> or bacteria associated with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> has not been examined.</p>
<p><a name="p69561221357159759"></a><span class="Italics">Cross-resistance:</span> Approximately 38% of <span class="Italics">T. vaginalis</span> isolates exhibiting reduced susceptibility to metronidazole also show reduced susceptibility to tinidazole <span class="Italics">in vitro.</span> The clinical significance of such an effect is not known.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">13  NONCLINICAL TOXICOLOGY</span></h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13-1"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><a name="p71911221357159759"></a>Metronidazole, a chemically-related nitroimidazole, has been reported to be carcinogenic in mice and rats but not hamsters.  In several studies metronidazole showed evidence of pulmonary, hepatic, and lymphatic tumorigenesis in mice and mammary and hepatic tumors in female rats.  Tinidazole carcinogenicity studies in rats, mice or hamsters have not been reported.</p>
<p><a name="p71941221357159759"></a>Tinidazole was mutagenic in the TA 100, <span class="Italics">S. typhimurium</span> tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> both with and without the metabolic activation system and was negative for mutagenicity in the TA 98 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>.  Mutagenicity results were mixed (positive and negative) in the TA 1535, 1537, and 1538 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.  Tinidazole was also mutagenic in a tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics"><span class="product-label-link" type="condition" conceptid="253790" conceptname="Pneumonia due to Klebsiella pneumoniae">Klebsiella pneumonia</span></span>.  Tinidazole was negative for mutagenicity in a mammalian cell culture system utilizing Chinese hamster lung V79 cells (HGPRT test system) and negative for genotoxicity in the Chinese hamster ovary (CHO) sister chromatid exchange assay.  Tinidazole was positive for <span class="Italics">in vivo</span> genotoxicity in the mouse micronucleus assay.</p>
<p><a name="p72091221357159759"></a>In a 60-day fertility study, tinidazole reduced fertility and produced testicular histopathology in male rats at a 600 mg/kg/day dose level (approximately 3-fold the highest human therapeutic dose based upon body surface area conversions).  Spermatogenic effects resulted from 300 and 600 mg/kg/day dose levels.  The no observed adverse reaction level for testicular and spermatogenic effects was 100 mg/kg/day (approximately 0.5-fold the highest human therapeutic dose based upon body surface area conversions).  This effect is characteristic of agents in the 5-nitroimidazole class.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13-2"></a><a name="section-12.2"></a><p></p>
<h2>13.2  Animal Toxicology and/or Pharmacology</h2>
<p class="First"><a name="p72171221357159759"></a>In acute studies with mice and rats, the LD<span class="Sub">50</span> for mice was generally &gt; 3,600 mg/kg for oral administration and was &gt; 2,300 mg/kg for intraperitoneal administration.  In rats, the LD<span class="Sub">50</span> was &gt; 2,000 mg/kg for both oral and intraperitoneal administration.</p>
<p><a name="p74341221357159759"></a>A repeated-dose toxicology study has been performed in beagle dogs using oral dosing of tinidazole at 100 mg/kg/day, 300 mg/kg/day, and 1000 mg/kg/day for 28-days.  On Day 18 of the study, the highest dose was lowered to 600 mg/kg/day due to severe clinical symptoms.  The two compound-related effects observed in the dogs treated with tinidazole were increased <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of the thymus in both sexes at the middle and high doses, and <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of the prostate at all doses in the males.  A no-adverse-effect level (NOAEL) of 100 mg/kg/day for females was determined.  There was no NOAEL identified for males because of minimal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of the prostate at 100 mg/kg/day (approximately 0.9-fold the highest human dose based upon plasma AUC comparisons).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">14  CLINICAL STUDIES</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14-1"></a><a name="section-13.1"></a><p></p>
<h2>14.1  <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">Trichomoniasis</span></h2>
<p class="First"><a name="p74491221357159759"></a>Tinidazole (2 g single oral dose) use in <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">trichomoniasis</span> has been well documented in 34 published reports from the world literature involving over 2,800 patients treated with tinidazole.  In four published, blinded, randomized, comparative studies of the 2 g tinidazole single oral dose where efficacy was assessed by culture at time points post-treatment ranging from one week to one month, reported cure rates ranged from 92% (37/40) to 100% (65/65) (n=172 total subjects).  In four published, blinded, randomized, comparative studies where efficacy was assessed by wet mount between 7-14 days post-treatment, reported cure rates ranged from 80% (8/10) to 100% (16/16) (n=116 total subjects).  In these studies, tinidazole was superior to placebo and comparable to other anti-trichomonal drugs.  The single oral 2 g tinidazole dose was also assessed in four open-label trials in men (one comparative to metronidazole and 3 single-arm studies).  Parasitological evaluation of the urine was performed both pre- and post-treatment and reported cure rates ranged from 83% (25/30) to 100% (80/80) (n=142 total subjects).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14-2"></a><a name="section-13.2"></a><p></p>
<h2>14.2  <span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">Giardiasis</span></h2>
<p class="First"><a name="p74571221357159759"></a>Tinidazole (2 g single dose) use in <span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">giardiasis</span> has been documented in 19 published reports from the world literature involving over 1,600 patients (adults and pediatric patients).  In eight controlled studies involving a total of 619 subjects of whom 299 were given the 2 g × 1 day (50 mg/kg × 1 day in pediatric patients) oral dose of tinidazole, reported cure rates ranged from 80% (40/50) to 100% (15/15).  In three of these trials where the comparator was 2 to 3 days of various doses of metronidazole, reported cure rates for metronidazole were 76% (19/25) to 93% (14/15).  Data comparing a single 2 g dose of tinidazole to usually recommended 5-7 days of metronidazole are limited.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14-3"></a><a name="section-13.3"></a><p></p>
<h2>14.3  Intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span></h2>
<p class="First"><a name="p74651221357159759"></a>Tinidazole use in intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> has been documented in 26 published reports from the world literature involving over 1,400 patients.  Most reports utilized tinidazole 2 g/day × 3 days.  In four published, randomized, controlled studies (1 investigator single-blind, 3 open-label) of the 2 g/day × 3 days oral dose of tinidazole, reported cure rates after 3 days of therapy among a total of 220 subjects ranged from 86% (25/29) to 93% (25/27).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14-4"></a><a name="section-13.4"></a><p></p>
<h2>14.4  Amebic <span class="product-label-link" type="condition" conceptid="201901" conceptname="Abscess of liver">Liver Abscess</span></h2>
<p class="First"><a name="p74731221357159760"></a>Tinidazole use in amebic <span class="product-label-link" type="condition" conceptid="201901" conceptname="Abscess of liver">liver abscess</span> has been documented in 18 published reports from the world literature involving over 470 patients.  Most reports utilized tinidazole 2 g/day × 2-5 days.  In seven published, randomized, controlled studies (1 double-blind, 1 single-blind, 5 open-label) of the 2 g/day × 2-5 days oral dose of tinidazole accompanied by <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> of the <span class="product-label-link" type="condition" conceptid="201901" conceptname="Abscess of liver">liver abscess</span> when clinically necessary, reported cure rates among 133 subjects ranged from 81% (17/21) to 100% (16/16).  Four of these studies utilized at least 3 days of tinidazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14-5"></a><a name="section-13.5"></a><p></p>
<h2>14.5  <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial Vaginosis</span></h2>
<p class="First"><a name="p76871221357159760"></a>A randomized, double-blind, placebo-controlled clinical trial in 235 non-pregnant women was conducted to evaluate the efficacy of tinidazole for the treatment of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>.  A clinical diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> was based on Amsel's criteria and defined by the presence of an abnormal homogeneous <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains ≥20% clue cells on microscopic examination.  Clinical cure required a return to normal <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> and resolution of all Amsel's criteria.  A microbiologic diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> was based on Gram stain of the vaginal smear demonstrating (a) markedly reduced or absent <span class="Italics">Lactobacillus</span> morphology, (b) predominance of <span class="Italics">Gardnerella</span> morphotype, and (c) absent or few white blood cells, with quantification of these bacterial morphotypes to determine the Nugent score, where a score ≥4 was required for study inclusion and a score of 0-3 considered a microbiologic cure.  Therapeutic cure was a composite endpoint, consisting of both a clinical cure and microbiologic cure.  In patients with all four Amsel's criteria and with a baseline Nugent score ≥4, tinidazole oral tablets given as either 2 g once daily for 2 days or 1 g once daily for 5 days demonstrated superior efficacy over placebo tablets as measured by therapeutic cure, clinical cure, and a microbiologic cure.</p>
<a name="t76981221357159760"></a><table width="58%">
<caption><span>Table 2. Efficacy of Tindamax in the Treatment of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial Vaginosis</span> in a Randomized, Double-Blind, Double-Dummy, Placebo-Controlled   Trial: Modified Intent-to-Treat Population<span class="Sup">1</span> (n=227)</span></caption>
<col align="center" valign="middle" width="32%">
<col align="center" valign="middle" width="24%">
<col align="center" valign="middle" width="24%">
<col align="center" valign="middle" width="20%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule" align="center" valign="top"> Outcome</td>
<td class="Lrule" align="center">Tindamax<br>1 g × 5 days<br>(n=76)</td>
<td class="Lrule" align="center">Tindamax<br>2 g × 2 days<br>(n=73)</td>
<td class="Lrule Rrule" align="center" valign="top">Placebo<br><br>(n=78)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"> </td>
<td class="Lrule" align="center">% Cure</td>
<td class="Lrule" align="center">% Cure</td>
<td class="Lrule Rrule" align="center">% Cure</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center" valign="top">
<br> Therapeutic  Cure<br><br>Difference<span class="Sup">2</span><br>97.5% CI<span class="Sup">3</span>
</td>
<td class="Lrule" align="center" valign="top">
<br>36.8<br><br>31.7<br>(16.8, 46.6)</td>
<td class="Lrule" align="center" valign="top">
<br>27.4<br><br>22.3<br>(8.0, 36.6)</td>
<td class="Lrule Rrule" align="center" valign="top">
<br>5.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center" valign="top">
<br> Clinical Cure<br><br>Difference<span class="Sup">2</span><br>97.5% CI<span class="Sup">3</span>
</td>
<td class="Lrule" align="center" valign="top">
<br>51.3<br><br>39.8<br>(23.3, 56.3)</td>
<td class="Lrule" align="center" valign="top">
<br>35.6<br><br>24.1<br>(7.8, 40.3)</td>
<td class="Lrule Rrule" align="center" valign="top">
<br>11.5</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center" valign="top">
<br> Nugent  Score Cure<br><br>Difference<span class="Sup">2</span><br>97.5% CI<span class="Sup">3</span>
</td>
<td class="Lrule" align="center" valign="top">
<br>38.2<br><br>33.1<br>(18.1, 48.0)</td>
<td class="Lrule" align="center" valign="top">
<br>27.4<br><br>22.3<br>(8.0, 36.6)</td>
<td class="Lrule Rrule" align="center" valign="top">
<br>5.1</td>
</tr>
</tbody>
</table>
<p><a name="p84861221357159760"></a><span class="Sup">1</span>Modified Intent-to-Treat defined as all patients randomized with a baseline<br>  Nugent score of at least 4<br><span class="Sup">2</span>Difference in cure rates (Tindamax-placebo)<br><span class="Sup">3</span>CI: confidence interval<br>  p-values for both Tindamax regimens vs. placebo for therapeutic, clinical and<br>  Nugent score cure rates for both 2 and 5 days &lt;0.001</p>
<p><a name="p87141221357159760"></a>The therapeutic cure rates reported in this clinical study conducted with Tindamax were based on resolution of 4 out of 4 Amsel's criteria and a Nugent score of &lt;4. The cure rates for previous clinical studies with other products approved for <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> were based on resolution of either 2 or 3 out of 4 Amsel's criteria. At the time of approval for other products for <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>, there was no requirement for a Nugent score on Gram stain, resulting in higher reported rates of cure for <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> for those products than for those reported here for tinidazole.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1><span class="Bold">16  HOW SUPPLIED/STORAGE AND HANDLING</span></h1>
<p class="First"><a name="p87241221357159760"></a>Tindamax 250 mg tablets are pink, round, scored tablets, with TM  debossed on one side and 250 on the other, supplied in bottles with child-resistant caps as:</p>
<p><a name="p87271221357159760"></a>NDC 0178-8250-40    Bottle of 40</p>
<p><a name="p87301221357159760"></a>Tindamax 500 mg tablets are pink, oval, scored tablets, with TM debossed on one side and 500 on the other, supplied in bottles with child-resistant caps as:</p>
<p><a name="p87331221357159760"></a>NDC 0178-8500-60    Bottle of 60<br>NDC 0178-8500-20    Bottle of 20</p>
<p><a name="p87381221357159760"></a><span class="Italics">Professional Samples:</span> </p>
<p><a name="p87441221357159760"></a>NDC 0178-8500-04    Bottle of 4</p>
<div class="Section" data-sectionCode="44425-7">
<a name="Gd2e2779"></a><a name="section-14.1"></a><p></p>
<h2></h2>
<p class="First"><a name="p87531221357159760"></a><span class="Italics">Storage:</span> Store at controlled room temperature 20-25° C (68-77° F); excursions permitted to 15-30° C (59-86° F) [see USP].  Protect contents from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1><span class="Bold">17  PATIENT COUNSELING INFORMATION</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S17-1"></a><a name="section-15.1"></a><p></p>
<h2>17.1  Administration of Drug</h2>
<p class="First"><a name="p89771221357159760"></a>Patients should be told to take Tindamax with food to minimize the incidence of <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span> and other gastrointestinal side-effects.  Food does not affect the oral bioavailability of tinidazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17-2"></a><a name="section-15.2"></a><p></p>
<h2>17.2  Alcohol Avoidance</h2>
<p class="First"><a name="p89851221357159760"></a>Patients should be told to avoid alcoholic beverages and preparations containing ethanol or propylene glycol during Tindamax therapy and for 3 days afterward because <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17-3"></a><a name="section-15.3"></a><p></p>
<h2>17.3  <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></h2>
<p class="First"><a name="p89931221357159760"></a>Patients should be counseled that antibacterial drugs including Tindamax should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>.  They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>).  When Tindamax is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Tindamax or other antibacterial drugs in the future.</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="g36905830-9f2a-31f7-bfcf-95c785b5bc88"></a><a name="section-16"></a><p></p>
<p class="First"><a name="p123222222"></a>Tindamax Label<br>0178-8500-20</p>
<div class="Figure"><img alt="Tindamax Label 0178-8500-20" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0d01539-8413-4703-94cc-d221918630a1&amp;name=TIN250mg_0606_40ct_label_NDC-0178-8250-20_C01.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="g9e7643b2-7f71-db1f-4dd7-47462a1f07b1"></a><a name="section-17"></a><p></p>
<p class="First"><a name="p1232211111"></a>Tindamax Label<br>NDC: 0178-8250-40</p>
<div class="Figure"><img alt="Tindamax Label 0178-8250-40" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0d01539-8413-4703-94cc-d221918630a1&amp;name=TIN250mg_0606_40ct_label_NDC-0178-8250-40_C01.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="g4237a28a-15e8-80a5-1fd9-11b5d1527218"></a><a name="section-18"></a><p></p>
<p class="First"><a name="p123223333"></a>Tindamax Label<br>0178-8500-60</p>
<div class="Figure"><img alt="Tindamax Label 0178-8500-60" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0d01539-8413-4703-94cc-d221918630a1&amp;name=TIN250mg_0606_40ct_label_NDC-0178-8250-60_C01.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TINDAMAX 		
					</strong><br><span class="contentTableReg">tinidazole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0178-8250</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Tinidazole</strong> (Tinidazole) </td>
<td class="formItem">Tinidazole</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (Pink) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Round) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TM;250</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0178-8250-40</td>
<td class="formItem">40  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021618</td>
<td class="formItem">05/17/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TINDAMAX 		
					</strong><br><span class="contentTableReg">tinidazole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0178-8500</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Tinidazole</strong> (tinidazole) </td>
<td class="formItem">Tinidazole</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (Pink) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Oval) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TM;500</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0178-8500-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0178-8500-20</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0178-8500-04</td>
<td class="formItem">4  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021618</td>
<td class="formItem">05/17/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mission Pharmacal Company
							(008117095)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Mission Pharmacal Company (927726893)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Mikart, Inc.</td>
<td class="formItem"></td>
<td class="formItem">030034847</td>
<td class="formItem">MANUFACTURE(0178-8250, 0178-8500)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>94492a08-570c-4176-a871-0977fd44d4fa</div>
<div>Set id: a0d01539-8413-4703-94cc-d221918630a1</div>
<div>Version: 3</div>
<div>Effective Time: 20130726</div>
</div>
</div> <div class="DistributorName">Mission Pharmacal Company</div></p>
</body></html>
